Skip to main navigation Skip to search Skip to main content

Cetuximab versus nimotuzumab for the treatment of advanced nasopharyngeal carcinoma: A network meta-analysis

  • Cheng Yuan
  • , Xin-Hua Xu*
  • , Lu Xu
  • , Yang Liu
  • , Min Sun
  • , Li-Hua Ni
  • , Xiao-Long Wang
  • , Zhuo Chen
  • , Kun Zhang
  • , Hua-Li Wan
  • , Guang Zeng
  • *Corresponding author for this work
  • China Three Gorges University
  • Yichang Cent Peoples Hosp
  • Southeast University - China
  • Technical University of Munich
  • State University of New York (SUNY) System

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

["Purpose: We conducted a network meta-analysis to evaluate the efficacy and toxicity of cetuximab and nimotuzumab in the treatment of advanced nasopharyngeal carcinoma (NPC).","Methods: A systematic literature search was performed though Pubmed, Embase, Cochran Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical (CBM) and Wanfang databases. Totally, 19 randomized controlled trials (RCTs) (n=1201) met the study selection criteria and were incorporated in this network meta analysis.","Results: Compared with cetuximab, the results of network meta-analysis indicated that nimotuzumab may achieve higher complete remission rate (CRR) or overall remission rate (ORR) of the primary tumor, but no difference was noticed in 1- and 2-year overall survival (OS) rate and certain toxicities such as myelosuppression, radiodermatitis, mucositis and gastrointestinal reactions. Although nimotuzumab increased the 3-year OS rate, compared with cetuximab, this result needs to be interpreted cautiously because of the studies' heterogeneity.","Conclusion: Even though we didn't find significant difference between cetuximab and nimotuzumab in terms of survival outcomes, nimotuzumab is more advantageous in short-term efficacy."]
Original languageEnglish
Pages (from-to)1004-1010
Number of pages7
JournalJournal of B.U.ON.
Volume22
Issue number4
StatePublished - Jul 2017

Funding

This study was funded by the Natural Science Foundation of Hubei Province, China (grant no. 2014CFB312), the Key Supporting Project of Scientific Research of Health and Family Planning Commission of Hubei Province, China (grant no.WJ20172026) and the Science Foundation of Hubei Key Laboratory of Tumor Microenvironment and Immunothrapy (grant no. 2015 KZL10).

Keywords

  • cetuximab
  • nasopharyngeal carcinoma
  • network meta-analysis
  • nimotuzumab

Indexed by

  • SCIE
  • Scopus

Fingerprint

Dive into the research topics of 'Cetuximab versus nimotuzumab for the treatment of advanced nasopharyngeal carcinoma: A network meta-analysis'. Together they form a unique fingerprint.

Cite this